FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	$D \subset$	205/10
vasiiiigioii,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIF
--

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	nd Address of																			
i ianan i	Name and Address of Reporting Person* Delegar Mickel					2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [AKBA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Dahan Michel</u>						Theola Therapeutics, Inc. [ARDA]							1	Director	r		10% Ow	ner		
					3. 0	ate o	of Earliest	Trans	saction (Mo	onth/	Day/Year)			$ \times$	Officer below)	(give title	give title Other (speci		pecify	
(Last) (First) (Middle) C/O AKEBIA THERAPEUTICS, INC.							05/24/2023								SVP, Chief Operating				,	
245 FIRS	ST STREET	Γ	4. 17	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable Line)							
(Street)											X		,		rting Persor					
CAMBR	IDGE M	IA	02142												Form filed by More than One Reporting Person					
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication																				
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											to									
		Tal	ble I - No	on-Deri	ivative	Se	curities	s Ac	quired,	Dis	posed o	of, or B	ene	ficially	Owned					
1. Title of S	Security (Ins	tr. 3)		2. Trans	action				3.									7. Nature of Indirect		
Date (Month/Day					Day/Year				Transaction Code (Instr. 3, 4 a			4 and 5)	Beneficially			(D) or Indirect	Beneficial			
						(Month/Day/Year)							Reported "		(I) (In		Ownership (Instr. 4)			
								Code	٧	Amount (A) or (D)		or	Price	Transaction(s) (Instr. 3 and 4)						
Common Stock 05/24/2				4/2023	2023		A		200,000) ⁽¹⁾ A	1	\$0.00	669	,515	D					
Common Stock 05/25/2				5/2023	2023		S		95,478 ⁽²⁾ D)	\$1.222	574,037			D				
			Table II	- Deriv	ative \$	Sec	urities	Acq	uired, D	isp	osed of	, or Be	nefic	cially (Owned					
				(e.g.,	puts,	call	ls, warr	ants	, option	ıs, (converti	ble se	urit	ies)						
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Execu (Month/Day/Year) if any	3A. Deeme Execution if any (Month/Da	Date,	4. Transac Code (In 8)				6. Date Exercis Expiration Dat (Month/Day/Ye		•	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	Ownersh Form: Direct (D or Indire (I) (Instr.	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	or Ni		mber Shares		(Instr. 4)				
Employee Stock Option (Right to	\$0.41	05/24/2023			A		200,000		(3)		05/12/2032	Common Stock	20	0,000	\$0.00	200,00	00	D		

Explanation of Responses:

- 1. As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023
- 2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs.
- 3. As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023.

Remarks:

/s/ Carolyn Rucci, attorney-infact for Michel Dahan

05/25/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.